



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Lyrica CR

Page: 1 of 2

Effective Date: 2/3/2023

Last Review Date:

| | | | |
|-------------|--|--|---------------------------------------|
| Applies to: | <input type="checkbox"/> Illinois | <input type="checkbox"/> Florida | <input type="checkbox"/> Florida Kids |
| | <input type="checkbox"/> New Jersey | <input checked="" type="checkbox"/> Maryland | <input type="checkbox"/> Michigan |
| | <input type="checkbox"/> Pennsylvania Kids | <input type="checkbox"/> Virginia | |

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Lyrica CR under the patient's prescription drug benefit.

Description:

Lyrica CR is indicated for the management of:

- Neuropathic pain associated with diabetic peripheral neuropathy
- Postherpetic neuralgia

Efficacy of Lyrica CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

Applicable Drug List:

Non-Formulary: Lyrica CR

Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- Lyrica CR (pregabalin extended-release) is being prescribed for the management of
 - postherpetic neuralgia OR
 - neuropathic pain associated with diabetic peripheral neuropathy

Approval Duration and Quantity Restrictions:

Approval: 12 months

Quantity Level Limit: Reference Formulary for drug specific quantity level limits

References:

1. Cymbalta [package insert]. Indianapolis, IN: Lilly USA, LLC; September 2021.
2. Lyrica [package insert]. New York, NY: Parke-Davis; June 2020.
3. Lyrica CR [package insert]. New York, NY: Parke-Davis; June 2020.
4. Neurontin [package insert]. New York, NY: Parke-Davis Division of Pfizer Inc; December 2020.



AETNA BETTER HEALTH®
Coverage Policy/Guideline

Name: Lyrica CR

Page: 2 of 2

Effective Date: 2/3/2023

Last Review Date:

| | | | |
|-------------|--|--|---------------------------------------|
| Applies to: | <input type="checkbox"/> Illinois | <input type="checkbox"/> Florida | <input type="checkbox"/> Florida Kids |
| | <input type="checkbox"/> New Jersey | <input checked="" type="checkbox"/> Maryland | <input type="checkbox"/> Michigan |
| | <input type="checkbox"/> Pennsylvania Kids | <input type="checkbox"/> Virginia | |

5. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Hudson, OH: UpToDate, Inc.; 2022; Accessed April 18, 2022.
6. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed April 18, 2022.
7. American Diabetes Association. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2022. *Diabetes Care* 2022;45(Suppl. 1): S185-S194.
8. Pop-Busui R, Boulton A, Feldman E, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. *Diabetes Care* 2017; 40:136–154.
9. Price R, Smith D, Franklin D et. al. Oral and Topical Treatment of Painful Diabetic Polyneuropathy: Practice Guideline Update Summary. Report of the AAN Guideline Subcommittee. *Neurology* 2022; 98:31-43.
10. NCCN Guidelines. Version 1.2022 Adult Cancer Pain. Available at http://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed April 2022.
11. Fisher RS, Cross JH, French JA, et al. Operational Classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017 Apr;58(4):522-530.